Forigerimod (Rigerimod) Medicine 09 January 2018 Extended indication Systemic Lupus erythematosus (SLE). Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance Forigerimod (Rigerimod) Domain Chronic immune diseases Reason of inclusion Main indication Other chronic immune diseases Extended indication Systemic Lupus erythematosus (SLE). Current proprietary name Already available biosimilars / generics Proprietary name Lupuzor Manufacturer ImmuPharma Portfolio holder Mechanism of action Unknown Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Unknown Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity New medicine ATMP Unknown Submission date Expected Registration 2019 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume < 357 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Een paar duizend patienten. In de beoordeling van Belimumab heeft het zorginstituut gerekend met: 'De prevalentie van SLE is 28-40 per 100,000 inwoners (~4.470 patiënten in Nederland). Ongeveer 8% van de patiënten met SLE heeft een hoge mate van ziekteactiviteit, ondanks een standaardbehandeling (zo’n 357 patiënten).' Expected cost per patient per year Cost References Prescribing outlook 2017 Additional remarks Waarschijnlijk hoge kosten Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks